Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in History
Oncolog, Volume 63, Number 07, July 2018, Sarah Bronson, Bryan Tutt
Oncolog, Volume 63, Number 07, July 2018, Sarah Bronson, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- FGFR Inhibition for Bladder Cancer: Erdafitinib has favorable response rate in advanced bladder cancers, including those that do not respond to immunotherapy
- INBRIEF: Targeted Therapies Matched to Tumor-Specific Mutations Prolong Survival
- Managing High-Risk Breast Lesions: Strong provider recommendation for preventive therapy increases its use in women with lobular carcinoma in situ, atypical hyperplasia
- Aerosolized Gemcitabine for Pulmonary Metastases: Clinical trials tests novel chemotherapy delivery system for patients with lung metastases from osteosarcoma or other solid tumors
- HOUSE CALL: What the national Cancer Institute Does- Resources for cancer patients, caregivers, physicians, researchers
Oncolog, Volume 63, Number 01, January 2018, Bryan Tutt
Oncolog, Volume 63, Number 01, January 2018, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Immunotherapy for Genitourinary Cancers: Clinical trials explore immune checkpoint inhibitors for bladder, kidney, prostate cancers
- Active Surveillance for Ductal Carcinoma in Situ: COMET trial compares frequent mammography to standard treatment with surgery
- Radiation Plus Chemotherapy for Nasal NK T Cell Lymphoma: Clinical trial may standardize treatment for rare cancer
- HOUSE CALL: Mammography Is Essential for Breast cancer Screening- FDA warns against clinics that advertise screening without mammography
- USEFULRESOURCES: Videoconferences Allow Collaboration in Cancer Prevention, Treatment, Survivorship